Detalles de la búsqueda
1.
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study.
Clin Chem
; 68(11): 1391-1398, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103292
2.
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
J Card Fail
; 28(12): 1673-1682, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36122820
3.
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Eur Heart J
; 40(40): 3345-3352, 2019 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31093657
4.
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
JAMA
; 322(11): 1085-1095, 2019 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31475295
5.
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction.
Circulation
; 146(18): 1411-1414, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36029463
6.
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Am Heart J
; 199: 130-136, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29754651
7.
Machine Learning for Proteomic Risk Scores in Heart Failure.
J Card Fail
; 29(11): 1583-1585, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37722615
8.
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Eur J Clin Pharmacol
; 74(9): 1121-1130, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29974143
9.
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
Clin Chem
; 59(6): 959-67, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23509108
10.
Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Eur Heart J
; 33(23): 2970-9, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22942337
11.
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.
JACC Heart Fail
; 11(1): 44-54, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599549
12.
Importance of the 'area under the curve' from serial NT-proBNP measurements during treatment with sacubitril/valsartan.
ESC Heart Fail
; 10(5): 3133-3140, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632309
13.
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
Circ Heart Fail
; 16(3): e010111, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36943907
14.
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
Circ Heart Fail
; 16(5): e010259, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125529
15.
Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Eur J Heart Fail
; 25(8): 1396-1405, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37401523
16.
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
Circulation
; 134(22): 1785-1787, 2016 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27895026
17.
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
Eur J Heart Fail
; 24(7): 1200-1208, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35560696
18.
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
JACC Heart Fail
; 10(2): 119-128, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35115085
19.
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
J Am Coll Cardiol
; 80(16): 1529-1541, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36229089
20.
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
JACC Heart Fail
; 10(12): 976-988, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36456072